The Role of α-Cell Dysregulation in Fasting and Postprandial Hyperglycemia in Type 2 Diabetes and Therapeutic Implications
The DOI matches its Crossref record; 313 of the 323 references it cites were found in a registry or an index.
Abstract
The hyperglycemic activity of pancreatic extracts was encountered some 80 yr ago during efforts to optimize methods for the purification of insulin. The hyperglycemic substance was named "glucagon," and it was subsequently determined that glucagon is a 29-amino acid peptide synthesized and released from pancreatic alpha-cells. This article begins with a brief overview of the discovery of glucagon and the contributions that somatostatin and a sensitive and selective assay for pancreatic (vs. gut) glucagon made to understanding the physiological and pathophysiological roles of glucagon. Studies utilizing these tools to establish the function of glucagon in normal nutrient homeostasis and to document a relative glucagon excess in type 2 diabetes mellitus (T2DM) and precursors thereof are then discussed. The evidence that glucagon excess contributes to the development and maintenance of fasting hyperglycemia and that failure to suppress glucagon secretion contributes to postprandial hyperglycemia is then reviewed. Although key human studies are emphasized, salient animal studies highlighting the importance of glucagon in normal and defective glucoregulation are also described. The past eight decades of research in this area have led to development of new therapeutic approaches to treating T2DM that have been shown to, or are expected to, improve glycemic control in patients with T2DM in part by improving alpha-cell function or by blocking glucagon action. Accordingly, this review ends with a discussion of the status and therapeutic potential of glucagon receptor antagonists, alpha-cell selective somatostatin agonists, glucagon-like peptide-1 agonists, and dipeptidyl peptidase-IV inhibitors. Our overall conclusions are that there is considerable evidence that relative hyperglucagonemia contributes to fasting and postprandial hyperglycemia in patients with T2DM, and there are several new and emerging pharmacotherapies that may improve glycemic control in part by ameliorating the hyperglycemic effects of this relative glucagon excess.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“in patients with T2DM elevated plasma glucagon levels have been observed in the fasting state, and defective suppression of glucagon secretion exists in the postprandial state, resulting in elevated plasma glucagon levels (7)”
From Mathematical Model of Glucagon Kinetics for the Assessment of Insulin-Mediated Glucagon Inhibition During an Oral Glucose Tolerance Test (2021) · cites this paper as [7]
In the citing paper
“dysregulated α-cell release of glucagon, manifest as increased fasting glucagon concentrations and a failure to adequately suppress glucagon release following meal ingestion, contributes to the development of hyperglycaemia34.”
From Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future (2014) · cites this paper as [34]
Citations
Cites
Hypothalamic Polypeptide That Inhibits the Secretion of Immunoreactive Pituitary Growth Hormone
Brazeau, P., Vale, W., Burgus, R., Ling, N., Butcher, M., Rivier, J., & Guillemin, R. (1973) · Science · doi:10.1126/science.179.4068.77 · Cited by 3,532
Immunoassay of endogenous plasma insulin in man
Yalow, R. S., & Berson, S. A. (1960) · Journal of Clinical Investigation · doi:10.1172/jci104130 · Cited by 3,041
Pathogenesis of NIDDM. A balanced overview.
DeFronzo, R. A., Bonadonna, R. C., & Ferrannini, E. (1992) · Diabetes Care · doi:10.2337/diacare.15.3.318 · Cited by 2,085
Methods of Hormone Radioimmunoassay
(1978) · Elsevier eBooks · doi:10.1016/b978-0-123-79260-0.x5001-8 · Cited by 2,077
Glucagon-like peptide-1 7–36: a physiological incretin in man
Kreymann, B., Ghatei, M. A., Williams, G., & Bloom, S. R. (1987) · The Lancet · doi:10.1016/s0140-6736(87)91194-9 · Cited by 1,928
DeFronzo, R. A., Ratner, R. E., Han, J., Kim, D. D., Fineman, M. S., & Baron, A. D. (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1092 · Cited by 1,559
(2004) · doi:10.1016/s0092-8674(04)00452-0 · Cited by 1,356
Buse, J. B., Henry, R. R., Han, J., Kim, D. D., Fineman, M. S., Baron, A. D., & for the Exenatide-113 Clinical Study Group (2004) · Diabetes Care · doi:10.2337/diacare.27.11.2628 · Cited by 1,346
Zander, M., Madsbad, S., Madsen, J. L., & Holst, J. J. (2002) · The Lancet · doi:10.1016/s0140-6736(02)07952-7 · Cited by 1,297
Dipeptidyl-peptidase IV (CD26)-role in the inactivation of regulatory peptides
Mentlein, R. (1999) · Regulatory Peptides · doi:10.1016/s0167-0115(99)00089-0 · Cited by 1,272
Research works printed but not linked: 9
- 2005, Sandostatin LAR depot (octreotide acetate for injectable suspension).
- 2005, Byetta (exenatide injection)[prescribing information].
- Pratley, 2005, Dipeptidyl peptidase-4 inhibition in type 2 diabetes mellitus., Sci Med, 10, 13
- Villhauer, 2001, DPP-IV inhibition and therapeutic potential., Annu Rep Med Chem, 36, 191
- Balas, J Clin Endocrinol Metab
- Dejager, Horm Metab Res
- Bosi, Diabetes Care
- Rosenstock, Diabetes Obes Metab
- Garber, Diabetes Obes Metab
Cited by
Items 301–400 of 421
Suppression of islet homeostasis protein thwarts diabetes mellitus progression
Oh, S., Jorgensen, M. L., Wasserfall, C. H., Gjymishka, A., & Petersen, B. E. (2017) · Laboratory Investigation · doi:10.1038/labinvest.2017.15 · Cited by 4
Discovery of Novel Glucagon Receptor Antagonists Using Combined Pharmacophore Modeling and Docking.
Jafari, F., Nowroozi, A., & Shahlaei, M. (2018) · PubMed Central · Cited by 4
Chen, X., Hermansen, K., & Jeppesen, P. B. (2012) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2012.01633.x · Cited by 4
Physiological and Pathophysiological Control of Glucagon Secretion by Pancreatic α-Cells
Gilon, P., Cheng, R., Lai, B. K., Chae, H., & Gómez-Ruiz, A. (2014) · Springer eBooks · doi:10.1007/978-94-007-6686-0_37 · Cited by 4
Xu, G., Gaul, M. D., Song, F., Du, F., Liang, Y. T., DesJarlais, R. L., Diloreto, K. A., Shook, B. C., Rentzeperis, D., Santulli, R., et al. (2019) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2019.126668 · Cited by 4
Glucagon in health and diabetes
Chawla, R., & Jaggi, S. (2023) · Journal of Diabetology · doi:10.4103/jod.jod_102_23 · Cited by 3
Barco, V. S., Gallego, F. Q., Miranda, C. A., de Souza, M. R., Volpato, G. T., & Damasceno, D. C. (2024) · Life Sciences · doi:10.1016/j.lfs.2024.122854 · Cited by 3
Interaction between Endocrine and Exocrine Pancreas
Mostafa, A., Gantsova, E. A., Serova, O. V., Mohammad, T., & Deyev, I. E. (2024) · Journal of Evolutionary Biochemistry and Physiology · doi:10.1134/s0022093024020273 · Cited by 3
Resistin in endocrine pancreas of sheep: Presence and expression related to different diets
Maranesi, M., Palmioli, E., Dall’Aglio, C., Marini, D., Anipchenko, P., Felice, E. D., Scocco, P., & Mercati, F. (2024) · General and Comparative Endocrinology · doi:10.1016/j.ygcen.2024.114452 · Cited by 3
Dipeptidyl Peptidase IV Inhibitors for Treatment of Diabetes
McIntosh, C. H. S., Kim, S. ‐., Pederson, R. A., Heiser, U. F., & Demuth, H. (2011) · Wiley eBooks · doi:10.1002/9780470910016.ch12 · Cited by 3
Le rôle du glucagon dans la physiopathologie du diabète
Lefèbvre, P. (2011) · Médecine des Maladies Métaboliques · doi:10.1016/s1957-2557(11)70206-1 · Cited by 3
Inulin might exceed incretin based drugs in the treatment of type 2 diabetes mellitus
Girgiss, M. W., Nicola, W. G., El-Arab, A. M. E., Habib, D. F., Ahmed, N. M., & Youness, E. R. (2019) · Biomedical & Pharmacology Journal · doi:10.13005/bpj/1732 · Cited by 3
Rafi, Q.-U.-A. S., Khairullah, Saeedullah, Arshia, A., Uddin, R., Atia-ul-Wahab, Khan, K. M., & Choudhary, M. I. (2023) · arXiv (Cornell University) · doi:10.48550/arxiv.2310.00947 · Cited by 3
Dai, H., & Zhang, Z. (2026) · Biomolecules · doi:10.3390/biom16040613 · Cited by 2
PANCREATIC ALPHA CELL DYSFUNCTION IN DIABETES MELLITUS AND ITS MANAGEMENT STRATEGIES
Pradhan, B., & Majhi, C. (2017) · Journal of Evidence Based Medicine and Healthcare · doi:10.18410/jebmh/2017/551 · Cited by 2
Effects of intraportal exenatide on hepatic glucose metabolism in the conscious dog
Edgerton, D. S., An, Z., Johnson, K., Farmer, T. E., Farmer, B., Neal, D. W., & Cherrington, A. D. (2013) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00160.2013 · Cited by 2
Targeting the AMP-regulated kinase family to treat diabetes: a research update
Sun, G., & Rutter, G. A. (2011) · Diabetes Management · doi:10.2217/dmt.11.11 · Cited by 2
Geary, N. (2013) · Elsevier eBooks · doi:10.1016/b978-0-12-385095-9.00150-0 · Cited by 2
Dinda, B., & Saha, S. (2022) · Springer eBooks · doi:10.1007/978-3-030-92196-5_1 · Cited by 2
Interaction of the Endocrine and Exocrine Parts of the Pancreas
Mostafa, A., Gantsova, E. A., Serova, O. V., Mohammad, T., & Deyev, I. E. (2024) · Российский физиологический журнал им И М Сеченова · doi:10.31857/s0869813924040019 · Cited by 2
Yabe, D., Kuroe, A., Ohya, M., Watanabe, K., Kitatani, N., Oku, M., Kurose, T., & Seino, Y. (2008) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2008.08.004 · Cited by 2
Hu, L., Zhang, Y., Wang, H., Peng, X.-Y., & Wang, Y. (2016) · Chinese Chemical Letters · doi:10.1016/j.cclet.2016.05.023 · Cited by 2
Clinical Approaches to Preserving b-Cell Function in Diabetes 33
WAJCHENBERG, B. L., & de Carvalho, R. M. (2015) · Cited by 1
Clinical Approaches to Preserving β-Cell Function in Diabetes
WAJCHENBERG, B. L., & de Carvalho, R. M. (2014) · Springer eBooks · doi:10.1007/978-94-007-6686-0_17 · Cited by 1
Estes, S. K., Shiota, C., O’Brien, T. P., Printz, R. L., & Shiota, M. (2024) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00192.2023 · Cited by 1
Tyrosine nitration of glucagon impairs its function: Extending the role of heme in T2D pathogenesis
Yin, X., Ni, G., Zhang, X., Fu, S., Li, H., & Gao, Z. (2024) · Journal of Inorganic Biochemistry · doi:10.1016/j.jinorgbio.2024.112519 · Cited by 1
Jiang, L., Zhou, L., Liu, J., & Wang, G. (2025) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2025.112207 · Cited by 1
Aikabeli, P. O., & Miracle, A. (2024) · Zenodo (CERN European Organization for Nuclear Research) · doi:10.5281/zenodo.14564708 · Cited by 1
α-cell SLC38A5 supports amino acid-induced α-cell proliferation and glucagon secretion
Sellick, K., Schornack, A. M. R., Rodgers, T. J., Ogodo, F. O., Aramandla, M. P., Stanley, J. E., Siv, W., Shou, M., Shankar, N. C., Saraf, S. S., et al. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1830329 · Cited by 1
Bewegung und Diabetes mellitus
Schröder, K., & Hamann, A. (2016) · Springer eBooks · doi:10.1007/978-3-662-50335-5_12 · Cited by 1
Facteurs de risque de diabète de type 2 chez l’individu non obèse
Bonnet, F. (2013) · Médecine des Maladies Métaboliques · doi:10.1016/s1957-2557(13)70493-0 · Cited by 1
Effects of glucose-dependent insulinotropic polypeptide on glucagon
Christensen, M., & Knop, F. K. (2016) · Cardiovascular Endocrinology · doi:10.1097/xce.0000000000000093 · Cited by 1
Glucagon in Islet and Metabolic Regulation
Sandoval, D. A., Tong, J., & Alessio, D. D. (2016) · Wiley eBooks · doi:10.1002/9781118924853.ch7 · Cited by 1
ADVANCES IN THE UNDERSTANDING OF PATHOPHYSIOLOGY OF TYPE 2 DIABETES MELLITUS
Ghosh, R. (2020) · International Journal of Medical Science and Diagnosis Research · Cited by 1
Rush, T. E. (2013) · The Scholarship East Carolina University's Institutional Repository (East Carolina University) · Cited by 1
Philippe, J. (2014) · theses.fr (ABES) · doi:10.70675/e6b37281za104z474az97d1z0766572c829a · Cited by 1
The Role of Glutamate Signalling In Diabetic Neuropathy
Hussain, N. (2014) · Cited by 1
Özköslü, M. A. (2019) · Hacettepe University Institutional Repository (hacettepe.edu.tr) · Cited by 1
Vily‐Petit, J. (2020) · theses.fr (ABES) · doi:10.70675/aaa9ce42z5f23z4953z8620z47e74ff7a235 · Cited by 1
Soty, M., Chilloux, J., Delalande, F., Zitoun, C., Bertile, F., Mithieux, G., & Gautier‐Stein, A. (2016) · Journal of Proteome Research · doi:10.1021/acs.jproteome.6b00284 · Cited by 1
Riboulet, W. (2015) · theses.fr (ABES) · doi:10.70675/08cb7cfaze244z48bcza3bfzab8c369434e4 · Cited by 1
NOX enzymes and ROS generation in human microglia, rodent inner ear, and pancreatic islets
Li, B. (2010) · Archive ouverte UNIGE (University of Geneva) · doi:10.13097/archive-ouverte/unige:5088
Juurinen, L. (2014) · Helda - University of Helsinki Institutional Repository
Mechanisms of ß-cell loss in male Munich Ins2C95S mutant mice
Kautz, S. (2010) · Elektronische Hochschulschriften der LMU München (Ludwig-Maximilians-Universität München) · doi:10.5282/edoc.11213
INCRETIN-BASED THERAPY IN THE MANAGEMENT OF TYPE 2 DIABETES
Ionescu-Tirgoviste, C., Davila, C., & Miulescu, R. D. (2010)
Di, Y. (2012) · RMIT Research Repository (RMIT University Library) · doi:10.25439/rmt.27332868
Fast-to-fed shift in glucose homeostasis: clues to an earlier detection of human prediabetic states
Patarrão, R. S. (2010) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT)
Cell culture models of insulin signalling and glucose uptake
Turner, M. C. (2015) · Loughborough University Research Repository (Loughborough University)
Merchant, C. E. (2011) · cIRcle (University of British Columbia) · doi:10.14288/1.0105089
Sensibilidade da molécula de insulina ao estado pós-prandial
Inácio, R. T. A. (2014) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT)
Selfa, M., & María, S. (2016) · LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas)
GLUTAMATE TRANSPORTERS IN PANCREAS AND EPITHELIA: PHYSIOLOGICAL ROLES AND DYNAMIC REGULATION
Cairano, E. S. D. (2010) · Archivio Istituzionale della Ricerca (Universita Degli Studi Di Milano) · doi:10.13130/di-cairano-eliana-sara_phd2010-12-20
Indications and Results of Coronarography in Senegalese Diabetic Patients: About 45 Cases
Ndao, S. C. T., Gaye, N. D., Dioum, M., Ngaide, A. A., Mingou, J. S., Ndiaye, M. B., Diao, M., & Ba, S. A. (2017) · Journal of Cardiology and Cardiovascular Medicine · doi:10.29328/journal.jccm.1001007
The metabolic effects of leptin therapy and glucagon suppression therapy in mouse models of diabetes
Neumann, U. H. (2017) · cIRcle (University of British Columbia) · doi:10.14288/1.0348695
Carranza, G. C., & Beatriz, Y. (2016) · Cybertesis (National University of San Marcos)
Add-on saxagliptin improves glycemic status among uncontrolled type 2 diabetes mellitus
Pradhan, B., Majhi, C., & Sahu, M. (2018) · International Journal of Research in Medical Sciences · doi:10.18203/2320-6012.ijrms20181758
Koffert, J. (2018) · UTUPub (University of Turku)
The pathogenesis of diabetes-tuberculosis comorbidity
Podell, B. K., Basaraba, R. J., Dow, S., Rovnak, J., Jackson, M., & Ishii, D. N. (2007) · Digital Collections of Colorado (Colorado State University) · doi:10.25675/3.021548
The peptides profile changes in tissues under the condition of experimental obesity in rats
Krenytska, D., Yurchenko, A., Lipets, N., & Savchuk, О. (2019) · Bulletin of Taras Shevchenko National University of Kyiv Series “Psychology” · doi:10.17721/1728_2748.2019.77.21-26
Pathophysiology of Type 2 diabetes mellitus & vascular disease
Forst, T. M., Theodor, R., & Weber, M. M. (2015) · doi:10.4155/fseb2013.13.108
The Evidence Base of Vildagliptin for T2DM Patient During Ramadan
Pranoto, A. S. (2017) · Universitas Airlangga Repository (Universitas Airlangga)
An, C., Zhang, K., Zhu, W., Bi, Y., Wu, T., Tao, C., Wang, Y., & Yang, S. (2020) · Canadian Journal of Animal Science · doi:10.1139/cjas-2019-0124
Huang, Y. (2012) · TSpace (University of Toronto)
FCoR-Foxo1 axis regulates α-cell mass through repression of Arx expression (本文)
小谷, 紀. (2019) · Institutional Repositories DataBase (IRDB)
Gruber, B. L. M. (2021) · Mspace (University of Manitoba)
Rosenzweig, S. A. (2009) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.1159871.621299
Clinical Approaches to Preserving β-Cell Function in Diabetes
WAJCHENBERG, B. L., & de Carvalho, R. M. (2014) · Springer eBooks · doi:10.1007/978-94-007-6884-0_17-3
Emerging Therapeutic Targets for Diabetes
(2016) · CRC Press eBooks · doi:10.1201/9781315370118-4
Ying, X., Ni, G., Zhang, X., Gao, Z., Fu, S., Li, H., & Gao, Z. (2023) · SSRN Electronic Journal · doi:10.2139/ssrn.4488896
Snapshot on a Possible Therapeutic Effect of Anti-diabetic Drugs in Gastric Ulcer
Hassan, S., Matouk, A. I., Anter, A. F., & Heeba, G. H. (2023) · Bulletin of Pharmaceutical Sciences Assiut · doi:10.21608/bfsa.2023.231823.1881
Novel insights into the physiological functions of glucagon
Gangopadhyay, K. K., & Mukherjee, J. J. (2023) · Journal of Diabetology · doi:10.4103/jod.jod_100_23
Pillai, J. S., Nair, P., Nandakumar, S., Thomson, R. J., & Pillai, S. S. (2023) · International Journal of Pharmaceutical Sciences and Drug Research · doi:10.25004/ijpsdr.2023.150302
Glucagon in Islet and Metabolic Regulation
Campbell, J. E., & D’Alessio, D. A. (2024) · Wiley eBooks · doi:10.1002/9781119697473.ch8
Chetty, K., Khathi, A., Schneider, S.-R., & Marx, G. (2023) · Series of Endocrinology Diabetes and Metabolism · doi:10.54178/jsedmv5i3001
Role of insulin-degrading enzyme in pancreatic alpha-cell function.
Casanueva-Álvarez, E. (2024) · UVaDOC UVaDOC University of Valladolid Documentary Repository (University of Valladolid) · doi:10.35376/10324/66862
Counteracting obesity through intestinal gluconeogenesis : the role of amino acids
Guo, C. (2022) · theses.fr (ABES) · doi:10.70675/ae34ea6fz1b8cz4418zb73dz453675c7a497
Andreozzi, F., Mancuso, E., Rubino, M., Salvatori, B., Morettini, M., Monea, G., Göbl, C. S., Mannino, G. C., & Tura, A. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1376530
原田, 範., & 稲垣, 暢. (2013) · 糖尿病 · doi:10.11213/tonyobyo.56.406
Ca2+i and the pancreatic α cell – intrinsic regulation and dysfunction in type 2 diabetes
Kellard, J. A. (2019) · Oxford University Research Archive (ORA) (University of Oxford) · doi:10.5287/ora-nzezaa8rn
Wang, H., Cao, J., Su, J., Wang, X.-Q., Wang, X., Zhang, D.-M., & Wang, X.-H. (2021) · Figshare · doi:10.6084/m9.figshare.14853057
Wang, H., Cao, J., Su, J.-B., Wang, X.-Q., Wang, X., Zhang, D.-M., & Wang, X.-H. (2021) · Figshare · doi:10.6084/m9.figshare.14853060
Yang, J., MacDougall, M. L., McDowell, M. T., Xi, L., Wei, R., Zavadoski, W. J., Molloy, M. P., Baker, J. D., Kuhn, M., Cabrera, O., et al. (2020) · Figshare · doi:10.6084/m9.figshare.12874143
Histone deacetylase inhibitor valproic acid in pancreas differentiation
Kandula, N. D., & Justus Liebig University Giessen (2020) · University writing server of the Justus Liebig University Giessen (Justus-Liebig-Universität Gießen) · doi:10.22029/jlupub-14832
Wang, H., Cao, J., Su, J.-B., Wang, X.-Q., Wang, X., Zhang, D.-M., & Wang, X.-H. (2021) · Figshare · doi:10.6084/m9.figshare.14853054
Wang, H., Cao, J., Su, J.-B., Wang, X.-Q., Wang, X., Zhang, D.-M., & Wang, X.-H. (2021) · Figshare · doi:10.6084/m9.figshare.14853063
Yang, J., MacDougall, M. L., McDowell, M. T., Xi, L., Wei, R., Zavadoski, W. J., Molloy, M. P., Baker, J. D., Kuhn, M., Cabrera, O., et al. (2020) · Figshare · doi:10.6084/m9.figshare.12874152
Yang, J., MacDougall, M. L., McDowell, M. T., Xi, L., Wei, R., Zavadoski, W. J., Molloy, M. P., Baker, J. D., Kuhn, M., Cabrera, O., et al. (2020) · Figshare · doi:10.6084/m9.figshare.12874146
Yang, J., MacDougall, M. L., McDowell, M. T., Xi, L., Wei, R., Zavadoski, W. J., Molloy, M. P., Baker, J. D., Kuhn, M., Cabrera, O., et al. (2020) · Figshare · doi:10.6084/m9.figshare.12874149
Hyperglukagonämie bei Diabetes mellitus
Korbas, S. (2013) · Dokumentenrepositorium der RUB (Ruhr University Bochum)
稲葉渉 (2015) · Institutional Repositories DataBase (IRDB)
Díaz Perdigones, C. M. (2023) · Repositorio Institucional de la Universidad de Málaga (University of Málaga)
Alaca, N. (2015) · Dspace Repository (Marmara Üniversitesi)
Genetic effects on intra-islet physiology and morphology in zebrafish
Walcher, A. (2019) · Digital Library of the University of Innsbruck (University of Innsbruck)
Hamilton, A. (2018) · Oxford University Research Archive (ORA) (University of Oxford) · doi:10.5287/ora-r5m40a4zd
Kahn, S. E., Tripputi, M., Lachin, J. M., Balasubramanyam, A., Banerji, M. A., Barzilay, J. I., Cohen, R. M., Garvey, W. T., Gramzinski, M. R., Rasouli, N., et al. (2025) · Diabetes Care · doi:10.2337/dc25-2186
ZEMB, P. A., & Joulia, F. (2026) · SSRN Electronic Journal · doi:10.2139/ssrn.6068352
Efficacy of Dual Glucagon and GLP-1 Agonists as New Treatments for Type II Diabetes
Vats, J., Chauhan, A., Rajput, S., Sridhar, S. B., Vashist, C., Mittal, A., & Malviya, R. (2026) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/0113895575419389251118100027
Metadata
- Authors
- Dunning, B. E., & Gerich, J. E.
- Affiliations
- PharmaWrite, Princeton, New Jersey 08540
- University of Rochester Medicine (US)
- Corresponding author
- Gerich, John E.
- Venue
- Endocrine Reviews
- Publisher
- The Endocrine Society
- Published
- 2007-04-04
- Volume
- 28
- Issue
- 3
- Pages
- 253-283
- ISSN
- 0163-769X (ISSN-L)
- 1945-7189
- OpenAlex
- W2088987697
- Cited by
- 369
- References
- 323
- Citations by year
- 2026: 6 · 2025: 7 · 2024: 16 · 2023: 17 · 2022: 14 · 2021: 20 · 2020: 15 · 2019: 21 · 2018: 17 · 2017: 24 · 2016: 25 · 2015: 23 · 2014: 24 · 2013: 27 · 2012: 27
- FWCI
- 2.77
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Endocrine Reviews (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Bristol-Myers Squibb
- Pfizer
- GlaxoSmithKline
- Sanofi
- University of Rochester
- Kowa Company
- Eisai
- Novo Nordisk
- Medical Center, University of Rochester
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- glucagon, alpha cells, type 2 diabetes, fasting hyperglycemia, postprandial hyperglycemia, hyperglucagonemia, glucagon receptor antagonists, somatostatin, GLP-1 receptor agonists, DPP-4 inhibitors, glucagon secretion, glycemic control, glucoregulation
- MeSH terms
- Animals, Diabetes Mellitus, Type 2, Fasting, Glucagon, Humans, Hyperglycemia, Receptors, Glucagon, Postprandial Period, Glucagon-Secreting Cells
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.